121 related articles for article (PubMed ID: 12402070)
21. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
22. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.
Kita T; Kikuchi Y; Takano M; Suzuki M; Oowada M; Konno R; Yamamoto K; Inoue H; Seto H; Yamamoto T; Shimizu K
Gynecol Oncol; 2004 Mar; 92(3):813-8. PubMed ID: 14984946
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
24. Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
Milović-Kovačević M; Stamatovic L; Popov I; Radošević-Jelić L; Kezic I
Med Sci Monit; 2010 Nov; 16(11):CR549-54. PubMed ID: 20980960
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
26. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy.
Doi D; Boh Y; Konishi H; Asakura H; Takeshita T
Arch Gynecol Obstet; 2009 Oct; 280(4):633-6. PubMed ID: 19205713
[TBL] [Abstract][Full Text] [Related]
27. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
29. [Second-line chemotherapy with paclitaxel for ovarian cancer].
Lehoczky O; Bagaméri A; Udvary J; Pulay T
Orv Hetil; 2001 Oct; 142(42):2299-301. PubMed ID: 11760646
[TBL] [Abstract][Full Text] [Related]
30. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Miolo G; Bidoli E; Lombardi D; Santeufemia DA; Capobianco G; Dessole F; Scalone S; Spazzapan S; Sorio R; Tabaro G; Veronesi A
Arch Gynecol Obstet; 2012 Feb; 285(2):499-503. PubMed ID: 21735184
[TBL] [Abstract][Full Text] [Related]
31. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
32. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
Coleman RL; Bagnell KG; Townley PM
Cancer J Sci Am; 1997; 3(4):246-53. PubMed ID: 9263631
[TBL] [Abstract][Full Text] [Related]
34. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
Storey DJ; Colvin LA; Mackean MJ; Mitchell R; Fleetwood-Walker SM; Fallon MT
J Pain Symptom Manage; 2010 Jun; 39(6):e2-4. PubMed ID: 20538177
[No Abstract] [Full Text] [Related]
35. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
[TBL] [Abstract][Full Text] [Related]
36. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
Abaid LN; Goldstein BH; Micha JP; Rettenmaier MA; Brown JV; Markman M
Oncology; 2010; 78(5-6):389-93. PubMed ID: 20798562
[TBL] [Abstract][Full Text] [Related]
37. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
38. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
39. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]